GlassScriptPhysician profile
Burak Erdinc
NPI 1780161117
$5,152.38
in general payments reported to CMS, 2019-2025
23 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,691 · 2023: $2,801 · 2024: $661.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,967 · Education: $495.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,966.59 |
| Education | $495.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $1,178.84 | 2022-2024 | Opdivo, Pomalyst, Augtyro |
| Seagen INC. | $492.56 | 2022-2023 | Adcetris |
| Genzyme Corporation | $460.34 | 2022-2024 | |
| Eisai INC. | $356.78 | 2022-2024 | |
| Genentech USA, INC. | $311.31 | 2022-2024 | Phesgo |
| Amgen INC. | $306.16 | 2023 | Blincyto, Kyprolis, Nplate |
| Astrazeneca Pharmaceuticals LP | $253.21 | 2023 | Imfinzi, Calquence |
| Lilly USA, LLC | $212.25 | 2023-2024 | Jaypirca, Verzenio |
| Janssen Biotech, INC. | $210.93 | 2022-2023 | Imbruvica, Darzalex, Erleada |
| Merck Sharp & Dohme LLC | $177.00 | 2023-2024 | Keytruda, Lynparza |
| Daiichi Sankyo INC. | $171.98 | 2023-2024 | Enhertu |
| Rigel Pharmaceuticals, INC. | $169.25 | 2022-2023 | Tavalisse, Rezlidhia |
| Glaxosmithkline, LLC. | $152.13 | 2022 | |
| Pfizer INC. | $127.93 | 2022-2024 | |
| Sumitomo Pharma America, INC. | $110.70 | 2023-2024 | Orgovyx |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $102.91 | 2022 | |
| Sanofi-Aventis U.S. LLC | $82.99 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $78.65 | 2023-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $57.00 | 2022-2024 | Alunbrig |
| Novartis Pharmaceuticals Corporation | $40.70 | 2022-2023 | |
| Puma Biotechnology, INC. | $40.61 | 2024 | |
| Array Biopharma INC | $35.81 | 2022 | |
| Celgene Corporation | $22.34 | 2023 | Reblozyl |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Burak Erdinc listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.